Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

NCT01386398 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

NETWORK

Sponsor class

Stopped Company withdrew interest

Conditions

Lymphoma

Interventions

DRUG: bortezomib
DRUG: vorinostat
OTHER: laboratory biomarker analysis

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC